Background Image
Table of Contents Table of Contents
Previous Page  161 / 1498 Next Page
Information
Show Menu
Previous Page 161 / 1498 Next Page
Page Background

90

Y-Ibritumomab consolidation confers a durable PFS benefit for

patients with advanced FL

• 3-year PFS advantage for patients in the ITT population

• At least a 6-year PFS advantage for patients with a

CR/CRu after induction > 5-year advantage in time to next

treatment

• No unexpected toxicities emerging

Annualized rate of secondary MDS/AML was 0.55% in the

Zevalin arm

FIT TRIAL

Conclusions after 7 years Follow-up